Among the three drugs, only abemaciclib has been approved as a monotherapy after the results of the MONARCH-1 phase 2 trial, which studied heavily pre-treated ER+/HER2− breast cancer patients who progressed on or after ET and chemotherapy. This evidence concerns the gene ESR1 and breast carcinoma.